Sarah Best
sarahannbest.bsky.social
Sarah Best
@sarahannbest.bsky.social
Co-lead Brain Cancer Research Lab @WEHI and Brain Cancer Centre in Australia
Reposted by Sarah Best
Researchers from WEHI, the Royal Melbourne Hospital & @petermaccc.bsky.social have achieved a brain cancer clinical trial world-first, providing hope to patients with low-grade gliomas.

🔗 www.wehi.edu.au/news/world-f...
August 22, 2025 at 10:31 PM
So incredibly proud of my team and our collaborators.
What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors

@braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social
@wehi-research.bsky.social

www.nature.com/articles/s41...
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial - Nature Medicine
This pilot trial showed that perioperative treatment with the isocitrate dehydrogenase (IDH) inhibitor safusidenib of patients with low-grade IDH-mutant glioma, with craniotomy and lumbar puncture bef...
www.nature.com
August 22, 2025 at 10:03 PM
Excited to share the latest review paper out of our Brain Cancer lab!
We focus a lot of our work on spatial heterogeneity and tumor microenvironment - but...how do you study it in practice? Read our review here discussing techniques and implications for GBM
www.sciencedirect.com/science/arti...
January 14, 2025 at 12:51 AM
Now on BioRxiv: we explored patient-derived GBM organoids & spheroids generated from the same resected tissue. Critically, both models maintain tumor cell composition & heterogeneity, with comparable tissue resemblance across data modalities (1/4)
www.biorxiv.org/content/10.1...
January 13, 2025 at 9:32 PM